CD274 and cancer: Immune checkpoint blockade targeting programmed death 1 (PD-1)/programmed death ligand 1 (PD-L1) and cytotoxic T lymphocyte-associated protein 4 (CTLA-4) has become a promising approach for anti-cancer immunotherapy (31).